Source: Eur Respir Rev 2013; 22: 58-65
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nico Derichs. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2013; 22: 58-65

Member's Comments

No comment yet.

Related content which might interest you: Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Source: Eur Respir Rev 2013; 22: 66-71 Year: 2013 Atypical cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38 Year: 2006 Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006 Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient Source: Eur Respir J 2002; 19: 374-376 Year: 2002 Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients Source: Eur Respir J 2004; 23: 679-684 Year: 2004 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 CFTR: cystic fibrosis and beyond Source: Eur Respir J 2014; 44: 1042-1054 Year: 2014 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 The cystic fibrosis transmembrane conductance regulator: state of the art Source: Breathe 2008; 5: 163-167 Year: 2008 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) ion transport Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016 Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001 Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019 High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and ΔF508 Source: Eur Respir J 2001; 17: 1181-1186 Year: 2001 A novel CFTR mutation found in a Chinese cystic fibrosis patient Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005 Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) Source: Breathe, 17 (3) 210088; 10.1183/20734735.0088-2021 Year: 2021